Cosmo First Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Specialty films sales have grown at a 13% CAGR over the last four years but remained flat in FY23 due to export market inventory corrections.
- Volume growth in Q4FY23 compared to Q4FY22 was 7%.
- The company expects demand growth of about 10% YoY going forward, especially from FMCG, textile, and consumption-driven industries.
- New production lines (2 in FY24, 5 more in FY25) will add capacity; however, a balanced demand-supply situation is anticipated over time.
- Specialty plus semi-specialty products are expected to constitute around 60-70% of total sales in about five years.
- Zigly pet care division aims for multiple times growth over the next couple of years, planning both organic and inorganic expansion including acquisitions.
- The BOPET, CPP, and BOPP line value-add CAPEX of Rs. 500-590 Cr to complete by March 2025 will support sales growth.
- A marginal margin uptick was noticed in May 2023, signaling improving business conditions.
See what Cosmo First management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company currently maintains a healthy financial position with a net debt/equity ratio of 0.3 times and a net debt/EBITDA ratio of 1 time, which they do not see as a concern.
- Management did not explicitly mention any upcoming fundraising through debt or equity.
- They are undertaking capex of around Rs. 590 Cr (value-add CAPEX on BOPP, BOPET, and CPP lines) and Rs. 100-150 Cr for the Zigly pet care business, but there is no indication of new fundraising to finance this.
- The company seems focused on internal cash flows and operational efficiencies to support growth and capex.
- They cited ongoing inorganic growth opportunities in pet care (Zigly acquisition), but no specific capital raising plans linked to these were disclosed.
- Overall, no current or immediate plans for debt/equity fundraising were mentioned in the transcript.
See what Cosmo First management said on order book — free account, 30 seconds.
Capex plans
Yes- The company has done close to Rs. 800 Cr CAPEX, with Rs. 590 Cr remaining for BOPP, CPP lines, and value-add assets on the BOPET line to be completed by March 2025.
- Remaining value-add CAPEX for the BOPET line is approximately Rs. 50 Cr.
- Planned capacity addition in BOPP and CPP lines is around 80,000 tons with a payback period close to four years.
- Zigly (pet care business) is expected to require Rs. 100-150 Cr CAPEX over the next 2-3 years, including operational losses.
- Chemical business may not require major CAPEX until 80% utilization is achieved.
- The company is pursuing strategic acquisitions in the online pet care space to accelerate growth, with one acquisition deal near finalization.
- Focus on sustainability includes sourcing 40-50% power from renewable sources, starting from May 2023, aiding cost rationalization.
Track Cosmo First — get its next earnings analysis in your feed
Margin guidance
Category 3- Specialty films portfolio expected to deliver superior returns despite near-term challenges in BOPP and BOPET films.
- Working on cost rationalization and R&D projects aimed at adding value in coming quarters and years.
- Zigly (pet care business) is growing rapidly, with break-even expected in 3 years; losses to peak in FY24 before improving FY25 onwards.
- Cosmo’s specialty chemical subsidiary aims to double revenue in coming years through new product launches.
- BOPET and related CAPEX (~Rs. 590 Cr total) focused on value-add assets, enhancing future revenue and margins.
- Commodity margins currently low (~1/5th of specialty), but specialty margins remain stable; Q4FY23 seen as bottomed out, with marginal uptick expected.
- Volume growth recorded at 7% in Q4FY23 vs Q4FY22.
- Renewable power sourcing and cost rationalization initiatives to improve profitability.
- CAPEX for new businesses (pet care and chemicals) to aid growth; peak debt manageable (Debt/EBITDA ~1:1).
Order book
How does Cosmo First rank vs peers in Industrial Products?
Pro featureHow does Cosmo First rank in Industrial Products?
Compare Cosmo First against every Industrial Products company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Cosmo First's management said in earlier quarters
Others in Industrial Products this season
- Mitsu Chem Plast (Q1 FY27)
Q1 FY27 showed strong profitability with EBITDA margin improving to 16.29% and net profit margin to 9.18%. Key concall takeaways from Mitsu Chem Plast Ltd's Q1…
- Simplex Castings Ltd (Q1 FY27)
Current capacity expansion planned for 300-350 crores revenue, further growth through organic or inorganic expansion. Key concall takeaways from Simplex…
- Astral (Q1 FY27)
Q1 FY27 plumbing value growth: 10.1%; volume flat for the quarter but strong growth post-April (Page 6, 26) . Key concall takeaways from Astral Ltd's Q1 FY27…
- CPL (Q1 FY27)
Ramp-up of Ahmedabad manufacturing facility over next 2-3 years to support volume growth and improve margins by 1%-1.5%. Key concall takeaways from Captain…